Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 4/20 | 0.34 |
| ▸ | HTR1B | P28222 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23833129 | 0.84 | ADRB2 (0.33) | HTR1DADRB2SLC1A5 | |
| SCHEMBL23833067 | 0.84 | — | — | |
| SCHEMBL26205645 | 0.79 | MRGPRX4 (0.43) | MRGPRX4HTR1DHTR1BKDM4ELMNA | |
| SCHEMBL28967256 | 0.78 | MRGPRX4 (0.38) | MRGPRX4HTR1DHTR1BKDM4ELMNA | |
| SCHEMBL23833022 | 0.77 | PKM (0.30) | — | |
| SCHEMBL23833166 | 0.75 | LTB4R (0.33) | ADRB2SLC1A5 | |
| SCHEMBL23833134 | 0.74 | AAK1 (0.48) | MRGPRX4 | |
| SCHEMBL22526336 | 0.74 | AAK1 (0.48) | MRGPRX4 | |
| SCHEMBL30192999 | 0.74 | AAK1 (0.48) | MRGPRX4 | |
| SCHEMBL23833132 | 0.74 | AAK1 (0.48) | MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-4121055-A1 | STAT DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021188696-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | MRGPRX4 3168/4885HTR1D 4246/4885HTR1B 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.